- Placement in pay group E9b TV-L, subject to fulfilling tariff requirements
- Full-time employment, currently 38.5 hours per week; part-time options available
- A state-of-the-art hematological specialized laboratory with molecular genetics, flow cytometry, and cytomorphology departments, one of the largest and most powerful in Germany
- Internal training and development opportunities at no cost to you
- Explore more exciting benefits of UKSH here
- Lead the Minimal Residual Disease (ALL) technical group, ensuring efficient organizational and technical processes
- Implement quality management in the workplace, equipment documentation, and quality control
- Drive changes in quantitative molecular procedures and optimize related processes
- Participate in validating and controlling the quality of established and new procedures, including international collaborations
- Manage laboratory requests in a laboratory information system and participate in internal and external audits
- Completed training as MTL, MTLA, BTA, CTA, or a Bachelor's degree in Life Sciences (Biomedicine, Human Biology, Molecular Medicine, Biotechnology, or similar) with relevant experience
- Passion for diagnosing leukemias and lymphomas
- Prior experience in molecular genetics, preferably in quantitative PCR assays (RQ-PCR and ddPCR), and hematological specialized diagnostics
- Knowledge of MRD analytics is a plus
- Proficient in PC skills (Word, Excel, Outlook, laboratory software, etc.)
MTA / MTL / MTLA (m/w/d) als Gruppenleitung - Minimale Resterkrankung (ALL) - Kiel, Deutschland - Universitätsklinikum Schleswig-Holstein
Beschreibung
Job Title: Technical Group Leader - Hematological Molecular Diagnostics
Company: Klinik für Innere Medizin II, Sektion für Hämatologische Spezialdiagnostik
Are you passionate about diagnosing hematological system diseases through molecular diagnostics? We are looking for your expertise as a Group Leader. Join our team for a challenging role where you will be involved in various research projects and therapy optimization studies, conducting analyses to detect residual disease in patients with ALL. You will establish patient-specific assays using RQ-PCR and ddPCR to monitor minimal residual disease and therapy progress.
Join Our Team
Come on board and support us for an initial period of 2 years with the possibility of extension.
What We Offer
What You'll Do
We promise thorough onboarding and continuous support from your colleagues. You are welcome to join us for a day of observation during the application phase.
Your Qualifications